NET CASH FROM OPERATING ACTIVITIES 2012 2011 Note $000 $000 Profit before tax 132,041 93,892 Adjustments for: Depreciation and amortisation of: Property, plant and equipment 42,359 35,660 Intangible assets 16,032 11,343 Loss on disposal of property, plant and equipment 349 22 Loss Gain on disposal of intangible assets 67 91 Movement on provisions 1,266 757 Movement on deferred income 62 87 Cost of equity-settled employee share scheme 7,961 7,507 Payments of costs directly attributable to acquisitions 5 1,519 10,147 Finance income 1,266 468 Interest and bank charges 35,717 23,368 Re sults from associates 892 1,164 Cash flow before changes in working capital 235,091 183,214 Change in trade and other receivables 20,759 59,898 Change in other current assets 2,259 4,570 Change in inventories 42,305 8,199 Change in trade and other payables 21,914 15,987 Change in other current liabilities 10,429 1,958 Cash generated by operations 206,629 128,492 Income tax paid 24,468 2,095 Net cash generated from operating activities 182,161 126,397 34.
CONTINGENT LIABILITIES A contingent liability existed at the balance sheet date in respect of guarantees and letters of credit totalling $120,554,000 2011: $82,494,000.
The integrated nature of the Groups worldwide operations, involving significant investment in research and strategic manufacturing at a limited number of locations, with consequential cross-border supply routes into numerous end-markets, gives rise to complexity and delay in negotiations with revenue authorities as to the profits on which individual Group companies are liable to tax.
Disagreements with, and between, revenue authorities as to intra-Group transactions, in particular the price at which goods and services should be transferred between Group companies in different tax jurisdictions, has the potential to produce conicting claims from revenue authorities as to the profits to be taxed in individual territories.
In common with many other companies in the pharmaceutical industry, the Group is involved in various legal proceedings considered typical to its business, including litigation relating to employment, product liability and other commercial disputes.
HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012 151
